Characterization of tumor mutation burden, PD-L1 and relationship to immune checkpoint inhibitors response

DOI: 10.1136/jitc-2019-000319

Citation Report

#	Article	IF	Citations
1	Biomarker Development for Metastatic Renal Cell Carcinoma: Omics, Antigens, T-cells, and Beyond. Journal of Personalized Medicine, 2020, 10, 225.	1.1	7
2	Predicting Response to Immunotherapy in Metastatic Renal Cell Carcinoma. Cancers, 2020, 12, 2662.	1.7	31
3	Predictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer. Frontiers in Oncology, 2020, 10, 1644.	1.3	48
4	COVID-19 and Kidney Disease: Molecular Determinants and Clinical Implications in Renal Cancer. European Urology Focus, 2020, 6, 1086-1096.	1.6	24
5	Update on the most promising biomarkers of response to immune checkpoint inhibitors in clear cell renal cell carcinoma. World Journal of Urology, 2021, 39, 1377-1385.	1.2	15
6	Tampering of Viruses and Bacteria with Host DNA Repair: Implications for Cellular Transformation. Cancers, 2021, 13, 241.	1.7	10
7	Pan-cancer Analysis of Tumor Mutational Burden and Homologous Recombination DNA Damage Repair Using Targeted Next-Generation Sequencing. Cancer Research and Treatment, 2021, 53, 973-982.	1.3	6
9	Individualizing renal cell carcinoma treatment through biomarkers discovery in the era of immune checkpoint inhibitors: where do we stand?. Current Opinion in Urology, 2021, 31, 236-241.	0.9	4
10	Pembrolizumab plus axitinib for the treatment of advanced renal cell carcinoma. Expert Review of Anticancer Therapy, 2021, 21, 693-703.	1.1	3
11	Metastatic Renal Cell Carcinoma Management: From Molecular Mechanism to Clinical Practice. Frontiers in Oncology, 2021, 11, 657639.	1.3	18
12	Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies. Cancer Discovery, 2021, 11, 874-899.	7.7	107
13	Tumor cell PD-L1 expression is a strong predictor of unfavorable prognosis in immune checkpoint therapy-naive clear cell renal cell cancer. International Urology and Nephrology, 2021, 53, 2493-2503.	0.6	11
14	TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor. , 2021, 9, e002127.		24
15	Homologous Recombination Repair Deficiency and Implications for Tumor Immunogenicity. Cancers, 2021, 13, 2249.	1.7	28
16	Biomarkers in renal cell carcinoma: Are we there yet?. Asian Journal of Urology, 2021, 8, 362-375.	0.5	15
17	Multitumor Case Series of Germline BRCA1, BRCA2 and CHEK2-Mutated Patients Responding Favorably on Immune Checkpoint Inhibitors. Current Oncology, 2021, 28, 3227-3239.	0.9	2
18	PDâ€1/PDâ€L1 inhibitorsâ€based treatment for advanced renal cell carcinoma: Mechanisms affecting efficacy and combination therapies. Cancer Medicine, 2021, 10, 6384-6401.	1.3	10
19	Eosinophil counts as a relevant prognostic marker for response to nivolumab in the management of renal cell carcinoma: a retrospective study. Cancer Medicine, 2021, 10, 6705-6713.	1.3	13

#	Article	IF	Citations
20	Comprehensive Genomic Landscape in Chinese Clear Cell Renal Cell Carcinoma Patients. Frontiers in Oncology, 2021, 11, 697219.	1.3	5
21	The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors. Journal of Cancer Research and Clinical Oncology, 2022, 148, 2427-2435.	1.2	5
22	PD-L1 Expression Is Significantly Associated with Tumor Mutation Burden and Microsatellite Instability Score. Cancers, 2021, 13, 4659.	1.7	20
23	Updates on Immunotherapy and Immune Landscape in Renal Clear Cell Carcinoma. Cancers, 2021, 13, 5856.	1.7	39
24	Predictive molecular markers for the treatment with immune checkpoint inhibitors in colorectal cancer. Journal of Clinical Laboratory Analysis, 2022, 36, e24141.	0.9	12
25	Prediction performance of twelve tumor mutation burden panels in melanoma and non-small cell lung cancer. Critical Reviews in Oncology/Hematology, 2022, 169, 103573.	2.0	2
26	Novel emerging biomarkers to immunotherapy in kidney cancer. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110593.	1.4	12
27	Analysis of Machine Learning Techniques for Detection Framework for DNA Repair Genes to help Diagnose Cancer: A Systematic Literature Review. , 2021, , .		1
28	Immunotherapy: A new standard in the treatment of metastatic clear cell renal cell carcinoma. World Journal of Clinical Oncology, 2022, 13, 28-38.	0.9	10
29	The Frontline Immunotherapy-Based Treatment of Advanced Clear Cell Renal Cell Carcinoma: Current Evidence and Clinical Perspective. Biomedicines, 2022, 10, 251.	1.4	13
30	Prognostic implication and immunotherapy response prediction of a costimulatory molecule signature in kidney renal clear cell carcinoma. Immunogenetics, 2022, , 1.	1.2	2
31	First-line Immune Checkpoint Inhibitor Combinations in Metastatic Renal Cell Carcinoma: Where Are We Going, Where Have We Been?. Drugs, 2022, 82, 439-453.	4.9	3
32	Immune Checkpoint Inhibitor Combination Therapy versus Sunitinib as First-Line Treatment for Favorable-IMDC-Risk Advanced Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical Trials. Biomedicines, 2022, 10, 577.	1.4	5
33	A Web-Based Prediction Model for Cancer-Specific Survival of Elderly Patients With Clear Cell Renal Cell Carcinoma: A Population-Based Study. Frontiers in Public Health, 2021, 9, 833970.	1.3	7
34	Biomarker discovery studies for patient stratification using machine learning analysis of omics data: a scoping review. BMJ Open, 2021, 11, e053674.	0.8	23
35	A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma. Clinical Cancer Research, 2022, 28, 3032-3041.	3.2	7
36	Tumor-immune microenvironment revealed by Imaging Mass Cytometry in a metastatic sarcomatoid urothelial carcinoma with a prolonged response to pembrolizumab.. Cold Spring Harbor Molecular Case Studies, 2022, 8, .	0.7	6
37	VHL and DNA damage repair pathway alterations as potential clinical biomarkers for first-line TKIs in metastatic clear cell renal cell carcinomas. Cellular Oncology (Dordrecht), 0, , .	2.1	2

#	Article	IF	Citations
38	The convergence of tumor suppressors on interferon pathway in kidney cancer and its therapeutic implication. American Journal of Physiology - Cell Physiology, 0, , .	2.1	1
39	Location matters: LAG3 levels are lower in renal cell carcinoma metastatic sites compared to primary tumors, and expression at metastatic sites only may have prognostic importance. Frontiers in Oncology, 0, 12, .	1.3	8
40	Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma. Nature Reviews Urology, 2023, 20, 133-157.	1.9	46
41	Comprehensive analysis of the expression profile and clinical implications of regulator of chromosome condensation 2 in pan-cancers. Aging, 2022, 14, 9221-9242.	1.4	6
43	IMAGENE trial: multicenter, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy of niraparib with PD-1 inhibitor in solid cancer patients with homologous recombination repair genes mutation. BMC Cancer, 2022, 22, .	1.1	0
46	Biological knowledge graph-guided investigation of immune therapy response in cancer with graph neural network. Briefings in Bioinformatics, 2023, 24, .	3.2	5
47	Combinations of Anti-Angiogenic Agents and Immune Checkpoint Inhibitors in Renal Cell Carcinoma: Best Option?. Cancers, 2023, 15, 1048.	1.7	1
49	BAP1-related signature predicts benefits from immunotherapy over VEGFR/mTOR inhibitors in ccRCC: a retrospective analysis of JAVELIN Renal 101 and checkmate-009/010/025 trials. Cancer Immunology, Immunotherapy, 2023, 72, 2557-2572.	2.0	2
50	Current Landscape of Genomic Biomarkers in Clear Cell Renal Cell Carcinoma. European Urology, 2023, 84, 166-175.	0.9	7
52	Understanding and integrating cytoreductive nephrectomy with immune checkpoint inhibitors in the management of metastatic RCC. Nature Reviews Urology, 2023, 20, 654-668.	1.9	2
62	Predictive Biomarkers in Advanced Renal Cell Carcinoma. , 2023, , 251-268.		0